UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]

OncoTargets and therapy, 2022-08, Vol.15, p.845-846

2022

Volltextzugriff (PDF)

The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer

Molecular biology reports, 2024-12, Vol.51 (1), p.174-174, Article 174

2024

Volltextzugriff (PDF)

Hereditary diffuse gastric cancer (HDGC). An overview

Clinics and research in hepatology and gastroenterology, 2022-04, Vol.46 (4), p.101820-101820, Article 101820

2022

Volltextzugriff (PDF)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Annals of oncology, 2007-09, Vol.18 (9), p.1529-1538

2007

Volltextzugriff (PDF)

Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate

International journal of oncology, 2011-12, Vol.39 (6), p.1491-1499

2011

Volltextzugriff (PDF)

Pharmacogenetics and pharmacoepigenetics of gemcitabine

Medical oncology (Northwood, London, England), 2010-12, Vol.27 (4), p.1133-1143

2010

Volltextzugriff (PDF)

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype

International journal of clinical pharmacology and therapeutics, 2011-08, Vol.49 (8), p.519

2011

Volltextzugriff (PDF)

Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer

European journal of gynaecological oncology, 2010, Vol.31 (4), p.386-391

2010

Volltextzugriff (PDF)

Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy

Clinical cancer research, 2003-05, Vol.9 (5), p.1596

2003

Volltextzugriff (PDF)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

BMC cancer, 2005-04, Vol.5 (1), p.44-44, Article 44

2005

Volltextzugriff (PDF)

CORRIGENDUM

OncoTargets and therapy, 2022-08, Vol.15, p.845

2022

Volltextzugriff (PDF)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

OncoTargets and therapy, 2018-01, Vol.11, p.8823-8833

2018

Volltextzugriff (PDF)

Neuroendocrine Marker Expression in Cervical Carcinomas of Non-Small Cell Type

International journal of gynecological pathology, 2002-10, Vol.21 (4), p.368-374

2002

Volltextzugriff (PDF)

Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients

International journal of cancer, 2003-05, Vol.104 (6), p.663-668

2003

Volltextzugriff (PDF)

Correlation of tumor growth index with early treatment response in cervical carcinoma

Journal of experimental & clinical cancer research, 2002-03, Vol.21 (1), p.57-63

2002

Volltextzugriff (PDF)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance

BMC cancer, 2005-06, Vol.5 (1), p.65-65, Article 65

2005

Volltextzugriff (PDF)

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation

Lung cancer (Amsterdam, Netherlands), 2005-11, Vol.50 (2), p.259-263

2005

Volltextzugriff (PDF)

Membrane proteins in neoplasic and normal uterine cervix

Journal of experimental & clinical cancer research, 2001-06, Vol.20 (2), p.231-237

2001

Volltextzugriff (PDF)

Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma

American journal of clinical oncology, 2003-02, Vol.26 (1), p.22-25

2003

Volltextzugriff (PDF)

Epigenetic changes in nucleoside transporter hENT1 and dCK, as mechanism for gemcitabine-aquired resistance in cervical cancer cell lines

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13633-e13633

2010

Volltextzugriff (PDF)

A phase II trial of epigenetic therapy with hydralazine and magnesium valproate associated to doxorubicin and cyclophosphamide for locally advanced breast cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13147-13147

2006

Volltextzugriff (PDF)

Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection

Immunology letters, 1999-04, Vol.67 (3), p.167-177

1999

Volltextzugriff (PDF)

Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene

Mutation research, 2000-09, Vol.452 (2), p.231-236

2000

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(17)
Oncology
(14)
Female
(13)
Adult
(9)
Middle Aged
(8)
Aged
(7)
Biological And Medical Sciences
(6)
Hydralazine
(6)
Medical Sciences
(6)
Uterine Cervical Neoplasms - Drug Therapy
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Epigenetics
(4)
Neoplasm Staging
(4)
Adolescent
(3)
Animals
(3)
Antineoplastic Agents
(3)
Biotechnology & Applied Microbiology
(3)
Deoxycytidine - Analogs & Derivatives
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]

The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer

Hereditary diffuse gastric cancer (HDGC). An overview

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate

Pharmacogenetics and pharmacoepigenetics of gemcitabine

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype

Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer

Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

CORRIGENDUM

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

Neuroendocrine Marker Expression in Cervical Carcinomas of Non-Small Cell Type

Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients

Correlation of tumor growth index with early treatment response in cervical carcinoma

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation

Membrane proteins in neoplasic and normal uterine cervix

Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma

Epigenetic changes in nucleoside transporter hENT1 and dCK, as mechanism for gemcitabine-aquired resistance in cervical cancer cell lines

A phase II trial of epigenetic therapy with hydralazine and magnesium valproate associated to doxorubicin and cyclophosphamide for locally advanced breast cancer

Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection

Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene

Suchergebnisse filtern